Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Nesp Biosame to Hit Japan Shelves on August 5
Nearly a year after its first-of-a-kind approval and ensuing debates surrounding its pricing, the so-called “biosame” version of Kyowa Kirin’s flagship renal anemia drug Nesp (darbepoetin alfa) will finally arrive on the Japanese market on August 5. “We developed this…
To read the full story
Related Article
- Nesp’s Biosame Switches Rapid but Expected: Kyowa Kirin President
February 7, 2020
- Kyowa Kirin Nets 12.6% Growth on Positive Sales Overseas; Biosame Trounces Nesp in Q4
February 6, 2020
- Nesp Biosame Soon to Leapfrog Originator as 5.6 Billion Yen Logged in Just 2 Months
October 30, 2019
- Kissei to Leverage Its Track Record with EPO to Promote Nesp Biosimilar: President
October 4, 2019
- Nesp Biosame Priced at 62.8-69.2% of Originator
June 14, 2019
- Chuikyo OKs 70% Pricing for Nesp Biosame; New Rules Up for FY2020 Reform Debate
March 28, 2019
- Nesp Biosame to Hit Japan Market in July-September 2019
October 31, 2018
BUSINESS
- Sanofi Delays Japan Launch of Efluelda by One Year, Defers NIP Rollout
July 22, 2026
- Takara Bio to Transfer Cell Processing CDMO Biz to S-RACMO
July 22, 2026
- Takara Bio Voluntary Buyout Draws 148 Employees
July 22, 2026
- Rhythm Pharma Gears Up for First Japan Launch with 50-Strong Team
July 21, 2026
- Fujifilm Toyama Chemical Forms 1st Product-Dedicated Unit for Savyscus
July 21, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…